皮肤恶性黑色素瘤的治疗进展
Advances in the Treatment of Cutaneous Malignant Melanoma
摘要: 皮肤恶性黑色素瘤(CMM)是一种具有高度侵袭性的皮肤恶性肿瘤，早期即可发生淋巴或血行转移，致死率高。早期明确诊断及规范化手术治疗是改善预后的关键。而随着近年来分子靶向治疗和免疫治疗的快速发展，晚期CMM尤其是局部不可切除或转移性患者的治疗效果得到明显改善，但未来仍需不断探索。文章就CMM治疗现状进行综述，以期为临床实践提供参考。
Abstract: Cutaneous malignant melanoma (CMM) is a highly aggressive skin malignancy that can metastasize via the lymphatic or hematogenous routes at an early stage, resulting in a high mortality rate. Early accurate diagnosis and standardized surgical treatment are critical to improving prognosis. With the rapid advancements in molecular targeted therapy and immunotherapy in recent years, the treatment outcomes for advanced CMM, particularly in patients with unresectable or metastatic disease, have significantly improved. However, further exploration is needed in the future. This article reviews the current status of CMM treatment to provide a reference for clinical practice.
文章引用：吴欣哲, 葛新红. 皮肤恶性黑色素瘤的治疗进展[J]. 临床医学进展, 2025, 15(3): 1936-1943. https://doi.org/10.12677/acm.2025.153822

参考文献

[1] Eriksson, H., Frohm-Nilsson, M., Järås, J., Kanter-Lewensohn, L., Kjellman, P., Månsson-Brahme, E., et al. (2015) Prognostic Factors in Localized Invasive Primary Cutaneous Malignant Melanoma: Results of a Large Population-Based Study. British Journal of Dermatology, 172, 175-186. [Google Scholar] [CrossRef] [PubMed]
[2] Arnold, M., de Vries, E., Whiteman, D.C., Jemal, A., Bray, F., Parkin, D.M., et al. (2012) Global Burden of Cutaneous Melanoma Attributable to Ultraviolet Radiation in 2012. International Journal of Cancer, 143, 1305-1314. [Google Scholar] [CrossRef] [PubMed]
[3] Kawakami, A. and Fisher, D.E. (2017) The Master Role of Microphthalmia-Associated Transcription Factor in Melanocyte and Melanoma Biology. Laboratory Investigation, 97, 649-656. [Google Scholar] [CrossRef] [PubMed]
[4] Feigelson, H.S., Powers, J.D., Kumar, M., Carroll, N.M., Pathy, A. and Ritzwoller, D.P. (2019) Melanoma Incidence, Recurrence, and Mortality in an Integrated Healthcare System: A Retrospective Cohort Study. Cancer Medicine, 8, 4508-4516. [Google Scholar] [CrossRef] [PubMed]
[5] Hawkes, J.E., Truong, A. and Meyer, L.J. (2016) Genetic Predisposition to Melanoma. Seminars in Oncology, 43, 591-597. [Google Scholar] [CrossRef] [PubMed]
[6] Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M., et al. (2018) The Commensal Microbiome Is Associated with Anti-PD-1 Efficacy in Metastatic Melanoma Patients. Science, 359, 104-108. [Google Scholar] [CrossRef] [PubMed]
[7] 陈万青, 郑荣寿, 曾红梅, 等. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2015, 24(1): 1-10.
[8] Wang, Y., Shi, L., Wang, L., Xu, J. and Feng, Y. (2015) Protective Effects of MDG-1, a Polysaccharide from Ophiopogon Japonicus on Diabetic Nephropathy in Diabetic KKAy Mice. International Journal of Molecular Sciences, 16, 22473-22484. [Google Scholar] [CrossRef] [PubMed]
[9] Buja, A., Rugge, M., Trevisiol, C., Zanovello, A., Brazzale, A.R., Zorzi, M., et al. (2024) Cutaneous Melanoma in Adolescents and Young Adults. Journal of the European Academy of Dermatology and Venereology, 38, 1997-2004. [Google Scholar] [CrossRef] [PubMed]
[10] Shi, Y., Huang, C., Yi, H., Cao, Q., Zhao, Y., Chen, J., et al. (2020) RIPK3 Blockade Attenuates Kidney Fibrosis in a Folic Acid Model of Renal Injury. The FASEB Journal, 34, 10286-10298. [Google Scholar] [CrossRef] [PubMed]
[11] 中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组. 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0 [J]. 中华肿瘤杂志, 2020, 42(2): 81-93.
[12] Coit, D.G., Thompson, J.A., Albertini, M.R., Barker, C., Carson, W.E., Contreras, C., et al. (2019) Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 367-402. [Google Scholar] [CrossRef] [PubMed]
[13] Joyce, D. and Skitzki, J.J. (2020) Surgical Management of Primary Cutaneous Melanoma. Surgical Clinics of North America, 100, 61-70. [Google Scholar] [CrossRef] [PubMed]
[14] Kimbrough, C.W., McMasters, K.M. and Davis, E.G. (2014) Principles of Surgical Treatment of Malignant Melanoma. Surgical Clinics of North America, 94, 973-988. [Google Scholar] [CrossRef] [PubMed]
[15] Ling, J., Tauscher, R., Mehta, V., Zhang, M., Daniels, A. and Kohanim, S. (2017) The Role for Sentinel Lymph Node Biopsy in the Management of Conjunctival Melanoma. International Ophthalmology Clinics, 57, 87-101. [Google Scholar] [CrossRef] [PubMed]
[16] Morton, D.L., Thompson, J.F., Cochran, A.J., Mozzillo, N., Nieweg, O.E., Roses, D.F., et al. (2014) Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. New England Journal of Medicine, 370, 599-609. [Google Scholar] [CrossRef] [PubMed]
[17] Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., et al. (2016) Complete Lymph Node Dissection versus No Dissection in Patients with Sentinel Lymph Node Biopsy Positive Melanoma (DeCOG-SLT): A Multicentre, Randomised, Phase 3 Trial. The Lancet Oncology, 17, 757-767. [Google Scholar] [CrossRef] [PubMed]
[18] Fioranelli, M., Roccia, M.G., Pastore, C., Aracena, C.J. and Lotti, T. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. Dermatologic Therapy, 30, e12544. [Google Scholar] [CrossRef] [PubMed]
[19] Howard, J.H., Thompson, J.F., Mozzillo, N., Nieweg, O.E., Hoekstra, H.J., Roses, D.F., et al. (2012) Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of Surgical Oncology, 19, 2547-2555. [Google Scholar] [CrossRef] [PubMed]
[20] Abdel-Rahman, O. (2017) Clinical Correlates and Prognostic Value of Different Metastatic Sites in Patients with Malignant Melanoma of the Skin: A SEER Database Analysis. Journal of Dermatological Treatment, 29, 176-181. [Google Scholar] [CrossRef] [PubMed]
[21] Balch, C.M., Gershenwald, J.E., Soong, S., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. (2009) Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology, 27, 6199-6206. [Google Scholar] [CrossRef] [PubMed]
[22] Raigani, S., Cohen, S. and Boland, G.M. (2017) The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Current Oncology Reports, 19, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
[23] Dumitraşcu, T., Dima, S., Popescu, C., et al. (2008) An Unusual Indication for Central Pancreatectomy—Late Pancreatic Metastasis of Ocular Malignant Melanoma. Chirurgia (Bucharest, Romania: 1990), 103, 479-485.
[24] Kim, S.H., Li, M., Trousil, S., Zhang, Y., Pasca di Magliano, M., Swanson, K.D., et al. (2017) Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma. Journal of Investigative Dermatology, 137, 1740-1748. [Google Scholar] [CrossRef] [PubMed]
[25] 张珉, 钟武. 黑色素瘤治疗新组合-Nivolumab和Ipilimumab [J]. 临床药物治疗杂志, 2017, 15(1): 79-84.
[26] Lopes, J., Rodrigues, C.M.P., Gaspar, M.M. and Reis, C.P. (2022) Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14, Article 4652. [Google Scholar] [CrossRef] [PubMed]
[27] Maio, M., Grob, J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., et al. (2015) Five-Year Survival Rates for Treatment-Naive Patients with Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 33, 1191-1196. [Google Scholar] [CrossRef] [PubMed]
[28] Tarhini, A.A., Lee, S.J., Hodi, F.S., Rao, U.N.M., Cohen, G.I., Hamid, O., et al. (2020) Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. Journal of Clinical Oncology, 38, 567-575. [Google Scholar] [CrossRef] [PubMed]
[29] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine, 366, 2443-2454. [Google Scholar] [CrossRef] [PubMed]
[30] Weber, J.S., D’Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. (2015) Nivolumab versus Chemotherapy in Patients with Advanced Melanoma Who Progressed after Anti-Ctla-4 Treatment (Checkmate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet Oncology, 16, 375-384. [Google Scholar] [CrossRef] [PubMed]
[31] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372, 2521-2532. [Google Scholar] [CrossRef] [PubMed]
[32] Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Lao, C.D., et al. (2022) Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone versus Ipilimumab in Patients with Advanced Melanoma. Journal of Clinical Oncology, 40, 127-137. [Google Scholar] [CrossRef] [PubMed]
[33] Richtig, G., Hoeller, C., Kashofer, K., Aigelsreiter, A., Heinemann, A., Kwong, L.N., et al. (2017) Beyond the BRAFV600e Hotspot: Biology and Clinical Implications of Rare BRAF Gene Mutations in Melanoma Patients. British Journal of Dermatology, 177, 936-944. [Google Scholar] [CrossRef] [PubMed]
[34] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAFV600E Mutation. New England Journal of Medicine, 364, 2507-2516. [Google Scholar] [CrossRef] [PubMed]
[35] Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., et al. (2015) Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAFV600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PharmacoEconomics, 33, 893-904. [Google Scholar] [CrossRef] [PubMed]
[36] Manzano, J.L., Layos, L., Bugés, C., de los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., et al. (2016) Resistant Mechanisms to BRAF Inhibitors in Melanoma. Annals of Translational Medicine, 4, 237-237. [Google Scholar] [CrossRef] [PubMed]
[37] Signorelli, J. and Shah Gandhi, A. (2016) Cobimetinib. Annals of Pharmacotherapy, 51, 146-153. [Google Scholar] [CrossRef] [PubMed]
[38] Amagai, R., Muto, Y., Kato, H., Matsushita, S., Maekawa, T., Fukushima, S., et al. (2021) Retrospective Analysis of Adjuvant Therapy Using Dabrafenib Plus Trametinib in Japanese Patients with Advanced Melanoma: Analysis of 36 Cases. Melanoma Research, 31, 575-578. [Google Scholar] [CrossRef] [PubMed]
[39] Ribas, A., Hodi, F.S., Callahan, M., Konto, C. and Wolchok, J. (2013) Hepatotoxicity with Combination of Vemurafenib and Ipilimumab. New England Journal of Medicine, 368, 1365-1366. [Google Scholar] [CrossRef] [PubMed]

为你推荐